全文获取类型
收费全文 | 14170篇 |
免费 | 1128篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 101篇 |
儿科学 | 495篇 |
妇产科学 | 303篇 |
基础医学 | 2028篇 |
口腔科学 | 101篇 |
临床医学 | 1904篇 |
内科学 | 2910篇 |
皮肤病学 | 225篇 |
神经病学 | 1429篇 |
特种医学 | 331篇 |
外科学 | 1399篇 |
综合类 | 147篇 |
一般理论 | 20篇 |
预防医学 | 1742篇 |
眼科学 | 165篇 |
药学 | 973篇 |
中国医学 | 16篇 |
肿瘤学 | 1045篇 |
出版年
2024年 | 28篇 |
2023年 | 236篇 |
2022年 | 290篇 |
2021年 | 580篇 |
2020年 | 375篇 |
2019年 | 629篇 |
2018年 | 620篇 |
2017年 | 415篇 |
2016年 | 462篇 |
2015年 | 453篇 |
2014年 | 566篇 |
2013年 | 829篇 |
2012年 | 1234篇 |
2011年 | 1221篇 |
2010年 | 595篇 |
2009年 | 542篇 |
2008年 | 847篇 |
2007年 | 880篇 |
2006年 | 858篇 |
2005年 | 780篇 |
2004年 | 646篇 |
2003年 | 620篇 |
2002年 | 578篇 |
2001年 | 79篇 |
2000年 | 62篇 |
1999年 | 80篇 |
1998年 | 100篇 |
1997年 | 104篇 |
1996年 | 70篇 |
1995年 | 69篇 |
1994年 | 40篇 |
1993年 | 50篇 |
1992年 | 36篇 |
1991年 | 28篇 |
1990年 | 25篇 |
1989年 | 23篇 |
1988年 | 20篇 |
1987年 | 18篇 |
1986年 | 12篇 |
1985年 | 8篇 |
1984年 | 19篇 |
1983年 | 21篇 |
1982年 | 21篇 |
1981年 | 29篇 |
1980年 | 14篇 |
1979年 | 9篇 |
1978年 | 13篇 |
1977年 | 29篇 |
1976年 | 17篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Georg Prokop Benedikt Wiestler Daniel Hieber Fynn Withake Karoline Mayer Jens Gempt Claire Delbridge Friederike Schmidt-Graf Nicole Pfarr Bruno Märkl Jürgen Schlegel Friederike Liesche-Starnecker 《International journal of cancer. Journal international du cancer》2023,153(9):1658-1670
Intratumor heterogeneity is a main cause of the dismal prognosis of glioblastoma (GBM). Yet, there remains a lack of a uniform assessment of the degree of heterogeneity. With a multiscale approach, we addressed the hypothesis that intratumor heterogeneity exists on different levels comprising traditional regional analyses, but also innovative methods including computer-assisted analysis of tumor morphology combined with epigenomic data. With this aim, 157 biopsies of 37 patients with therapy-naive IDH-wildtype GBM were analyzed regarding the intratumor variance of protein expression of glial marker GFAP, microglia marker Iba1 and proliferation marker Mib1. Hematoxylin and eosin stained slides were evaluated for tumor vascularization. For the estimation of pixel intensity and nuclear profiling, automated analysis was used. Additionally, DNA methylation profiling was conducted separately for the single biopsies. Scoring systems were established to integrate several parameters into one score for the four examined modalities of heterogeneity (regional, cellular, pixel-level and epigenomic). As a result, we could show that heterogeneity was detected in all four modalities. Furthermore, for the regional, cellular and epigenomic level, we confirmed the results of earlier studies stating that a higher degree of heterogeneity is associated with poorer overall survival. To integrate all modalities into one score, we designed a predictor of longer survival, which showed a highly significant separation regarding the OS. In conclusion, multiscale intratumor heterogeneity exists in glioblastoma and its degree has an impact on overall survival. In future studies, the implementation of a broadly feasible heterogeneity index should be considered. 相似文献
2.
Rizzo Manglio Miguel Bluthgen Mara Virginia Recondo Gonzalo Naveira Martin Perfetti Aldo Rizzi Florencia Kuzminin Alejandro Faura Victoria Cerini Matas Videla Alejandro Silva Carlos Lupinacci Lorena Minatta Nicols 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1057-1064
International Journal of Clinical Oncology - Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status... 相似文献
3.
4.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
5.
6.
7.
Anne Pavy-Le Traon Richard L Hughson Claire Thalamas Monique Galitsky Nelly Fabre Olivier Rascol Jean-Michel Senard 《Movement disorders》2006,21(12):2122-2126
Patients with multiple system atrophy (MSA) present large changes in blood pressure (BP) due to autonomic disturbances. We analyzed how this change may influence dynamic cerebral autoregulation (DCA). Simultaneous recordings of arterial BP (Finapres) and middle cerebral artery (MCA) blood flow velocity (BFV) (transcranial Doppler) were performed in 10 patients with MSA (61 +/- 12 yr of age) and 12 healthy volunteers (61 +/- 11 yr of age): cerebral BFV response to oscillations in mean BP was studied in the supine position by cross-spectral analysis of mean BP and mean MCA BFV. The DCA was also studied during the decrease in BP the first seconds when standing up from a sitting position by the assessment of the cerebrovascular resistance index (CR; mean BP/mean MCA BFV ratio). The MCA BFV/BP cross-spectral analysis showed a phase for the mid-frequency band (0.07-0.2 Hz) significantly larger in MSA, suggesting more active autoregulation in response to larger changes in BP. Changes in CR reflecting the rate of autoregulation, when standing did not differ between the two groups. These data suggest that dynamic cerebral autoregulation is preserved in MSA. 相似文献
8.
Reliable procedure for the production of 1-[(11)C]acetate in GMP conditions was developed based on a combination of the captive-solvent Grignard reaction conducted in the sterile catheter followed by the convenient solid-phase extraction purification on a series of ion-exchange cartridges. The described procedure proved to be reliable in more than 30 patient productions. The process provides stable radiochemical yields (65% EOB) of sodium acetate (1-[(11)C]) of the Ph.Eur. quality (radiochemical purity better than 95%) in a short time (5 min). 相似文献
9.
Claire M Rickard Brigit L Roberts Jonathon Foote Matthew R McGrail 《Dimensions of critical care nursing》2006,25(5):234-242
Research coordinators in intensive care are a growing specialty about which little is known. This cross-sectional study surveyed the Australia and New Zealand Intensive Care Research Coordinators' Group (n = 49) regarding demographics, education, employment history, job structure, and role content. Most research coordinators were highly qualified and experienced nurses who undertake pharmaceutical trials, multicenter projects, departmental medical and nursing research, audits and data registries, and their own projects. 相似文献
10.
J.-P. Coudereau Marcel Debray Claire Monier Jean-Marie Bourre Henriette Frances 《Psychopharmacology》1997,130(2):117-123
Morphine (8–100 mg/kg IP) induces place preference conditioning in mice. The effect of two different periods of isolation
(15 and 30 days) was examined. Mice isolated for 15 days but not 30 days exhibited place preference conditioning to morphine
(8 mg/kg). After 30 days of isolation morphine could not induce place preference conditioning with the following doses (8, 16, 64, 100 mg/kg).
Social regrouping of male mice previously isolated for 30 days with naive female mice for 15 or 30 days resulted in a reappearance
of the conditioned place preference to morphine (16 mg/kg). The specificity of this associative deficit was examined by testing
learning in isolated compared to non-isolated mice in two distinct settings: escape learning in the Morris water maze and
passive avoidance acquisition and retention. On the Morris water maze isolated mice did not differ from non-isolated mice
regarding place learning, the probe trial or extinction. Isolated mice were unimpaired in passive avoidance acquisition and
retention. It was concluded that the deficits in place preference conditioning were not the result of a global learning impairment
in isolated mice.
Received: 10 April 1996 /Final version: 20 September 1996 相似文献